Division of Pediatric Infectious Diseases, Department of Pediatrics, The University of Texas Medical Branch, Galveston.
Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, Galveston.
JAMA Pediatr. 2014 Jan;168(1):68-75. doi: 10.1001/jamapediatrics.2013.3924.
Otitis media (OM) is a leading cause of pediatric health care visits and the most frequent reason children consume antibiotics or undergo surgery. During recent years, several interventions have been introduced aiming to decrease OM burden.
To study the trend in OM-related health care use in the United States during the pneumococcal conjugate vaccine (PCV) era (2001-2011).
DESIGN, SETTING, AND PARTICIPANTS: An analysis of an insurance claims database of a large, nationwide managed health care plan was conducted. Enrolled children aged 6 years or younger with OM visits were identified.
Annual OM visit rates, OM-related complications, and surgical interventions were analyzed.
Overall, 7.82 million unique children (5.51 million child-years) contributed 6.21 million primary OM visits; 52% were boys and 48% were younger than 2 years. There was a downward trend in OM visit rates from 2004 to 2011, with a significant drop that coincided with the advent of the 13-valent vaccine (PCV-13) in 2010. The observed OM visit rates in 2010 (1.00/child-year) and 2011 (0.81/child-year) were lower than the projected rates based on the 2005-2009 trend had there been no intervention (P < .001). Recurrent OM (≥3 OM visits within 6-month look-back) rates decreased at 0.003/child-year (95% CI, 0.002-0.004/child-year) in 2001-2009 and at 0.018/child-year (95% CI, 0.008-0.028/child-year) in 2010-2011. In the PCV-13 premarket years, there was a stable rate ratio (RR) between OM visit rates in children younger than 2 years and in those aged 2 to 6 years (RR, 1.38; 95% CI, 1.38-1.39); the RR decreased significantly (P < .001) during the transition year 2010 (RR 1.32; 95% CI, 1.31-1.33) and the postmarket year 2011 (RR 1.01; 95% CI, 1.00-1.02). Tympanic membrane perforation/otorrhea rates gradually increased (from 3721 per 100,000 OM child-years in 2001 to 4542 per 100,000 OM child-years in 2011; P < .001); the increase was significant only in the older children group. Mastoiditis rates substantially decreased (from 61 per 100,000 child-years in 2008 to 37 per 100,000 child-years in 2011; P < .001). Ventilating tube insertion rate decreased by 19% from 2010 to 2011 (P = .03).
There was an overall downward trend in OM-related health care use from 2001 to 2011. The significant reduction in OM visit rates in 2010-2011 in children younger than 2 years coincided with the advent of PCV-13. Although tympanic membrane perforation/otorrhea rates steadily increased during that period, mastoiditis and ventilating tube insertion rates decreased in the last years of the study.
重要性:中耳炎(OM)是导致儿科就诊的主要原因,也是儿童使用抗生素或接受手术的最常见原因。近年来,已经引入了几种干预措施,旨在减轻 OM 的负担。
目的:研究美国在肺炎球菌结合疫苗(PCV)时代(2001-2011 年)与 OM 相关的医疗保健使用趋势。
设计、地点和参与者:对大型全国性管理医疗保健计划的保险索赔数据库进行了分析。确定了有 OM 就诊的 6 岁或以下儿童。
主要结果和措施:分析了每年 OM 就诊率、OM 相关并发症和手术干预情况。
结果:总体而言,780 万独特儿童(551 万儿童年)贡献了 621 万例原发性 OM 就诊;52%为男孩,48%小于 2 岁。从 2004 年到 2011 年,OM 就诊率呈下降趋势,2010 年 13 价疫苗(PCV-13)问世后出现显著下降。2010 年(1.00/儿童年)和 2011 年(0.81/儿童年)观察到的 OM 就诊率低于根据 2005-2009 年趋势预测的就诊率(P <.001)。复发性 OM(6 个月回顾期间有≥3 次 OM 就诊)的发生率在 2001-2009 年期间以每年 0.003/儿童年(95%CI,0.002-0.004/儿童年)的速度下降,在 2010-2011 年期间以每年 0.018/儿童年(95%CI,0.008-0.028/儿童年)的速度下降。在 PCV-13 上市前的几年里,2 岁以下儿童和 2 至 6 岁儿童的 OM 就诊率之间的稳定率比(RR)为 1.38(95%CI,1.38-1.39);在 2010 年过渡年(RR 1.32;95%CI,1.31-1.33)和 2011 年上市后年(RR 1.01;95%CI,1.00-1.02)显著下降(P <.001)。鼓膜穿孔/耳漏率逐渐增加(从 2001 年的每 100,000 OM 儿童年 3721 例增加到 2011 年的每 100,000 OM 儿童年 4542 例;P <.001);仅在较大儿童组中观察到增加。乳突炎率大幅下降(从 2008 年的每 100,000 儿童年 61 例降至 2011 年的每 100,000 儿童年 37 例;P <.001)。通风管插入率从 2010 年到 2011 年下降了 19%(P =.03)。
结论和相关性:从 2001 年到 2011 年,与 OM 相关的医疗保健使用总体呈下降趋势。2010-2011 年 2 岁以下儿童 OM 就诊率的显著下降恰逢 PCV-13 的问世。尽管在此期间鼓膜穿孔/耳漏率稳步上升,但在研究的最后几年,乳突炎和通风管插入率下降。